StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project:[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
  1. Startseite
  2. /Verbindung

N,N-Dimethyl-10H-phenothiazin-10-propanamin

Promazine

HCID 4926
NotizenReaktionen
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
58-40-2
Standard-SMILES
CN(C)CCCN1c2ccccc2Sc2ccccc21
InChIKey
ZGUGWUXLJSTTMA-UHFFFAOYSA-N
Summenformel
C17H20N2S
Durchschnittliche Molmasse
284,4 g/mol
Monoisotopische Masse
284,13471982

Überblick

Promazine is a phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position. It has a role as a phenothiazine antipsychotic drug, a H1-receptor antagonist, a serotonergic antagonist, a dopaminergic antagonist, a muscarinic antagonist, an antiemetic and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a tertiary amine and a member of phenothiazines.

Namen und Bezeichner

Bevorzugter Name
Promazine
IUPAC
N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
Lokaler Name
N,N-Dimethyl-10H-phenothiazin-10-propanamin
Englischer Name
Promazine
Summenformel
C17H20N2S
Molmasse
284.4191

Namen und Synonyme

promazine58-40-2PromazinAmpazinePromazinaPromwillRomtiazinSinopheninPrazinPrazineNeo-HibernexProtactyl
Weitere Namen anzeigen
A-145Wy-1094RP-3276NSC 31447Chlorpromazine-003Promazine USP/EP/BPPromazine Dimer Impurity
BerophenEsparinVerophenTomilPromazinumN-(3-Dimethylaminopropyl)phenothiazineN-Dimethylamino-1-methylethyl thiodiphenylamineCombelen

Datenbank-Bezeichner

CAS
58-40-2
PubChem CID
4926
DTXSID
DTXSID2023517
ChEMBL
CHEMBL564
ChEBI
CHEBI:8459
UNII
O9M39HTM5W
EC Number
200-382-0
Nikkaji
J2.805C

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,5
Polarare Oberfläche (TPSA)
31,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
4
Schwere Atome
20
Formalladung
0
Komplexität
285

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

DEA NFLIS-Drug Category -> Depressants and Tranquilizers

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

pHAlkaline reaction
LogP · 3 Einträge

log Kow= 4.55

4.3

4.64

OdorAmine odor
Color/FormOily liq
Solubility · 4 Einträge

Sol in methanol, ethanol, chloroform /Hydrochloride/

Practically insol in ether, benzene /Hydrochloride/

In water, 14.2 mg/l @ 24 °C

2.07e-02 g/L

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Boiling Point · 2 Einträge

203-210 °C at 3.00E-01 mm Hg

203-210 °C @ 0.3 mm Hg

DecompositionWhen heated to decomposition it emits very toxic fumes of nitroxides and sulfoxides.

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P272, P273, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, P391, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Sicherheit und Schutzausrüstung

Storage ConditionsThe product should be stored at controlled room temperature and protected from freezing and light.
Disposal Methods · 1 Eintrag

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxikologische Informationen

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Protein Binding94%
Pharmacodynamics · 1 Eintrag

Promazine belongs to a group of medications known as the phenothiazine antipsychotics. It acts by blocking a variety of receptors in the brain, particularly dopamine receptors. Dopamine is involved in transmitting signals between brain cells. When there is an excess amount of dopamine in the brain it causes over-stimulation of dopamine receptors. These receptors normally act to modify behaviour and over-stimulation may result in psychotic illness. Promazine hydrochloride blocks these receptors and stops them becoming over-stimulated, thereby helping to control psychotic illness. Promazine has weak extrapyramidal and autonomic side effects which lead to its use in the elderly, for restless or psychotic patients. Its anti-psychotic effect is also weaker and it is not useful in general psychiatry.

Mechanism of Action · 3 Einträge

Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.

THERE IS AN ADENYLATE CYCLASE IN LIMBIC SYSTEM, AS WELL AS IN CAUDATE NUCLEUS, THAT IS SPECIFICALLY ACTIVATED BY DOPAMINE. ...ACTIVATION OF...ENZYME IS... BLOCKED BY...PHENOTHIAZINES. ...THERAPEUTIC EFFICACY & SIDE EFFECTS MAY RELATE TO INHIBITION OF DOPAMINE ACTIVATION OF ADENYLATE CYCLASE. /PHENOTHIAZINES/

...PHENOTHIAZINES, BLOCK DOPAMINE RECEPTORS & INCR TURNOVER RATE OF DOPAMINE IN CORPUS STRIATUM. INCR TURNOVER RATE IS BELIEVED TO BE RESULT OF NEURONAL FEEDBACK MECHANISM. ...FIRING OF.../IDENTIFIED DOPAMINERGIC NEURONS IN SUBSTANTIA NIGRA & VENTRAL TEGMENTAL AREAS/ IS INCR BY ANTIPSYCHOTIC PHENOTHIAZINES. /PHENOTHIAZINES/

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Melting Point · 2 Einträge

< 25 °C

< 25 °C

Physical DescriptionSolid
Stability/Shelf Life · 2 Einträge

Promazine HCl is maximally stable at pH 6.5 /Promazine HCl/

OXIDIZES UPON PROLONGED EXPOSURE TO AIR & ACQUIRES BLUE OR PINK COLOR /HYDROCHLORIDE/

Physikochemische Eigenschaften

Schmelzpunkt
25 °C · 25°C
Siedepunkt
0.3 · bp0.3 203-210°
Dichte
1.1256 · 1.1256 (rough estimate)
Brechungsindex
1.6 · 1.6000 (estimate)
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
pka
9.4 · pKa 9.4(H2O,t =24±1) (Uncertain)
Aggregatzustand
Solid
Farbe
Off-White to Pale Beige
Wasserlöslichkeit
14.22 mg/L · 14.22mg/L(24 ºC)
Stabilität
Hygroscopic
NIST chemische Informationen
Promazine(58-40-2)
Treatment
In severe cases, consider supportive therapy. Maintain clear airway and adequate hydration. Anti-Parkinson drugs, as well as benztropine mesylate, and barbiturates can be use to relieve extrapyramidal symptoms (A632).
Interactions · 5 Einträge

RABBIT, RAT, & SHEEP TRIALS INDICATE IT MAY HELP REDUCE TOXIC EFFECTS OF CARBON TETRACHLORIDE. ... HAS INCR TOXICITY OF ORGANOPHOSPHORUS OR OTHER ACETYLCHOLINESTERASE INHIBITORS & PROCAINE.

...PHENOTHIAZINES...MAY PRODUCE ADDITIVE HYPOTENSIVE EFFECTS WITH PROPRANOLOL. /PHENOTHIAZINES/

...OTHER ANTIPSYCHOTIC DRUGS ... MAY BLOCK ANTIHYPERTENSIVE EFFECTS OF GUANETHIDINE ... /PHENOTHIAZINES/

Additive QT interval prolongation may increase the risk of ventricular tachycardia when /probucol is used with phenothiazines/. /Phenothiazines/

For more Interactions (Complete) data for PROMAZINE (31 total), please visit the HSDB record page.

Health Effects · 1 Eintrag

It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon either. Other effects include endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia (A308, L1149).

Exposure RoutesInhalation; dermal or skin contact; ingestion (MSDS, A308). Absorption may be erratic and peak plasma concentrations show large interindividual differences.
Milk ConcentrationsPHENOTHIAZINES ... MAY APPEAR IN MILK OF NURSING MOTHERS... /PHENOTHIAZINES, HUMAN, ORAL, IM/
Toxicity Summary · 1 Eintrag

Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.

Signs and SymptomsSide effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.
Human Toxicity Excerpts · 4 Einträge

HIGH DOSES...FOR PROLONGED PERIODS...STAR-SHAPED OPACITIES...IN ANTERIOR PORTION OF LENS...VISUAL IMPAIRMENT...EPITHELIAL KERATOPATHY, LACRIMATION...PIGMENTARY RETINOPATHY /CHRONIC TOXICITY, HYDROCHLORIDE/

LONG-TERM ADMIN OF HIGH DOSES...MAY RESULT IN PIGMENT DEPOSITIONS IN...BODY TISSUES...BRAIN, HEART, LIVER, KIDNEYS, RETINA..CORNEA /& SKIN, USUALLY YELLOWISH-BROWN BUT MAY BECOME GREYISH-PURPLE/. OCULAR CHANGES...DEPOSITION OF FINE PARTICULATE MATTER IN LENS & CORNEA /CHRONIC TOXICITY, HYDROCHLORIDE/

Sudden and unexpected deaths have occurred in patients receiving phenothiazines, especially during long-term administration of the drugs. In some patients, sudden death appeared to result from asphyxia (secondary to failure of the cough reflex) or cardiac arrest. /Phenothiazines/

In general, overdosage of phenothiazines may be expected to produce effects that are extensions of common adverse effects; severe extrapyramidal reactions, hypotension, and sedation have been the principal effects reported. CNS depression progressing to coma with areflexia may occur; patients with early or mild intoxication may experience restlessness, confusion, and excitement. Other reported effects associated with acute phenothiazine overdosage have included tachycardia, ECG changes and cardiac arrhythmias, hypothermia, miosis, tremor, muscle twitching, spasm or rigidity, seizures, muscular hypotonia, ileus, dry mouth, difficulty in swallowing or breathing, cyanosis, and respiratory and/or vasomotor collapse, possibly with sudden apnea. /Phenothiazines/

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Non-Human Toxicity Excerpts · 5 Einträge

...CERTAIN DEGREE OF BOTH LEUKOPENIA & LYMPHOCYTOSIS WAS REPORTED... SYMPTOMS OF OVERDOSAGE ARE DROP IN BLOOD PRESSURE, RESPIRATORY DEPRESSION & CIRCULATORY COLLAPSE.

HAS PRODUCED MARKED ARRHYTHMIAS IN BOTH ANESTHETIZED & ACTIVE UNANESTHETIZED DOGS.

PROMAZINE, PHENOTHIAZINE DERIVATIVE TRANQUILIZER HAS PRODUCED REVERSIBLE OPACITY OF FRONT OF LENS IN MICE...BUT NO RELATED EFFECT HAS BEEN NOTED IN HUMAN BEINGS.

PROMAZINE WAS TESTED FOR ABILITY TO INDUCE SISTER-CHROMATID EXCHANGES WITH & WITHOUT PHOTOACTIVATION BY VISIBLE LIGHT IN CHINESE HAMSTER CELL LINE V79 CLONES. IN THE DARK IT INCREASED THE FREQUENCY OF SISTER-CHROMATID EXCHANGES.

NONE OF PHENOTHIAZINES WAS MUTAGENIC IN DARK. MUTAGENICITY WAS OBSERVED ONLY IN STRAINS OF SALMONELLA TYPHIMURIUM THAT LACKED EXCISION REPAIR OF DNA & MUTAGENICITY WAS ELEVATED IN STRAINS WITH PLASMID PKM101.

Antidote and Emergency Treatment · 1 Eintrag

EXTRAPYRAMIDAL SYMPTOMS...RELIEVED WITH BARBITURATES, METHYLPHENIDATE HYDROCHLORIDE...ANTI-PARKINSON DRUGS...BENZTROPINE MESYLATE...TRIHEXYPHENIDYL HYDROCHLORIDE...DIPHENHYDRAMINE HYDROCHLORIDE...IN SEVERE CASES, SUPPORTIVE THERAPY...MAINTAINING CLEAR AIRWAY & ADEQUATE HYDRATION. /HYDROCHLORIDE/

Toxicity DataLD50: 140 mg/kg (Intraperitoneal, Mouse)

Regulatorische Informationen

FDA Requirements · 1 Eintrag

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Sicherheitsdaten

Toxizität
LD50 oral in rat: 350mg/kg
Giftige Stoffe Daten
58-40-2(Hazardous Substances Data)
Metabolism/Metabolites · 5 Einträge

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide.

YIELDS DEMETHYLPROMAZINE, PROMAZINE-N-OXIDE, & PROMAZINE SULFOXIDE IN MAN & IN RAT; YIELDS 3-HYDROXYPROMAZINE & PHENOTHIAZINE IN MAN. /FROM TABLE/

...METAB...BY OXIDATIVE PROCESSES MEDIATED LARGELY BY HEPATIC MICROSOMAL & OTHER DRUG-METABOLIZING ENZYMES. CONJUGATION WITH GLUCURONIC ACID...PROMINENT ROUTE.../PRC: REACTIONS INCL HYDROXYLATION, DEMETHYLATION, SULFOXIDE FORMATION; METABOLIC ALTERATIONS IN SIDE CHAIN MAY ALSO OCCUR/. /PHENOTHIAZINES/

Promazine has known human metabolites that include N-Desmethyl promazine and Promazine 5-sulfoxide.

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide. Absorption may be erratic and peak plasma concentrations show large interindividual differences. The metabolism occurs through oxidative processes mediated largely by hepatic microsomal and other drug metabolizing enzymes. Antoher step is the conjugaion with glucuronic acid. Other reactions include hydroxylation, demetylation, and sulfoxide formation. Moreover, metabolic alterations in side chain may also occur (A308, A631).

MeSH Pharmacological Classification · 3 Einträge

Drugs used to prevent NAUSEA or VOMITING.

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Absorption, Distribution and Excretion · 2 Einträge

Absorption may be erratic and peak plasma concentrations show large interindividual differences.

IV ADMIN RESULTS PEAK IN ABOUT 5 MIN, IM IN ABOUT 20-30 MIN, ORAL IN ABOUT 1-2 HR. PARENTERAL EFFECTS ARE MORE PREDICTABLE, & USUALLY REQUIRE ABOUT HALF ORAL DOSAGE FOR SOME COMPARABLE EFFECTS.

Cellular LocationsMembrane

Verwendung und Herstellung

Uses · 4 Einträge

MEDICATION (VET)

MEDICATION

Use (kg) in Switzerland (2009): >50

Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.

Methods of ManufacturingPrepd by heating xylene soln of phenothiazine & 3-dimethyl-amino-1-chloropropane in presence of sodamide: Charpentier, US patent 2,519,886 (1950 to Rhone-Poulenc).
Formulations/PreparationsPROMAZINE HYDROCHLORIDE NF...INJECTION NF: 25 & 50 MG/ML, 50 & 100 MG/2 ML, 250 & 500 MG/10 ML; SOLN NF: 30 MG & 100 MG/ML. SYRUP NF: 10 MG/5 ML; TABLETS NF: 10, 25, 50, 100, & 200 MG. /HYDROCHLORIDE/
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan
General Manufacturing Information · 3 Einträge

Incompatibilities: incompatible with alkalies, oxidizing agents, heavy metals.

FDA REGULATIONS ESTABLISH ZERO TOLERANCE FOR ITS RESIDUES ON OR IN UNCOOKED TISSUES OF FOOD PRODUCING ANIMALS.

A FEW AVAIL AGENTS...ARE NOW KNOWN TO HAVE INFERIOR ANTIPSYCHOTIC EFFECTS OR...ARE NO LONGER COMMONLY USED IN PSYCHIATRIC PT. THESE INCL...PROMAZINE...

Anwendungen · 1 Eintrag

VerwendenIn psychiatric practice, promazine is used in minor cases of psychomotor excitement in schizophrenics, in paranoid and manic-depressive conditions, for neurosis, alcoholic psychosis, and others. It is sometimes used in anesthesiological practice.

Anbieter27 Anbieter

北京华美互利生物化工010-56205725 · [email protected]
广州隽沐生物科技股份有限公司020-36607679; 13502246435 · [email protected]
广州隽唐科技有限公司020-36607679 13502246435 · [email protected]
梯希爱(上海)化工贸易有限公司021-61109150 · [email protected]
上海澜克医药科技有限公司021-52216295 lankepharma · [email protected]
宝鸡缔都医药化工有限公司029-81145305 17791533577 · [email protected]
Moxin Chemicals+86-17320513646 +86-17320513646 · [email protected]
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
深圳摩科生化科技有限公司18627923403 · [email protected]
郑州为易化工产品有限公司0371-88888888 qq272369594;2159423853qq · [email protected]
天津阿尔塔科技有限公司022-6537-8550 15522853686 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
Standardpharm Co. Ltd.86-714-3992388 · [email protected]
sgtlifesciences pvt ltd+91-8790379245 · [email protected]
BOC Sciences16314854226 · [email protected]
成都标样生物科技有限公司028-81700200 13308200041 · [email protected]
深圳市祥根生物医药有限公司0755-28967200 13631290199 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]
山东诚创蓝海医药科技有限公司15662783880 · [email protected]
山东诚创蓝海医药科技有限公司0531-58897130 15508676053 · [email protected]
深圳聚合生化科技有限公司+86-400-002-6226 13028896684 · [email protected]
深圳博泰尔生物技术有限公司13316949107 13316968096 · [email protected]
湖北摩科化学有限公司18627753421; 18627756402 · [email protected]
四川嘉瑛莱科技有限责任公司028-64159575 · [email protected]
重庆卡兰医药有限公司[email protected]
上海相辉医药科技有限公司13611835272 13611835272 · [email protected]
广州市震霖医药科技有限公司020-18102736 13622807357 · [email protected]

Ergänzende Hinweise

DefinitionChEBI: A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.